• LAST PRICE
    0.0416
  • TODAY'S CHANGE (%)
    Trending Down-0.0043 (-9.3682%)
  • Bid / Lots
    0.0416/ 100
  • Ask / Lots
    0.0455/ 100
  • Open / Previous Close
    0.0417 / 0.0459
  • Day Range
    Low 0.0415
    High 0.0455
  • 52 Week Range
    Low 0.0380
    High 0.4990
  • Volume
    133,509
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.0459
TimeVolumeAXIM
09:35 ET100000.0417
10:22 ET16000.0415
10:44 ET550000.0416
11:14 ET110010.041966
11:25 ET90000.0455
11:32 ET408700.0416
11:38 ET10000.041873
11:52 ET10000.0448
01:00 ET5000.0416
01:29 ET5000.0455
02:32 ET3750.0416
02:38 ET26600.0416
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAXIM
Axim Biotechnologies Inc
8.6M
-0.4x
---
United StatesOTIC
Otonomy Inc
8.8M
-0.2x
---
United StatesPKTX
ProtoKinetix Inc
8.8M
-4.1x
---
United StatesCYCC
Cyclacel Pharmaceuticals Inc
8.3M
-0.4x
---
United StatesBLPH
Bellerophon Therapeutics Inc
8.8M
-0.5x
---
United StatesLADX
LadRx Corp
8.2M
-0.6x
---
As of 2022-12-09

Company Information

AXIM Biotechnologies, Inc. is an international healthcare solutions company. The Company is focused on diagnosis and treatment for oncology and SARS-CoV-2, or COVID-19. The Company's COVID-19 rapid neutralizing antibody test ImmunoPass is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering human host cells. In addition, the Company is developing rapid diagnostic tests for the early detection of cancer and small molecules drugs to treat cancer and block metastasis. The Company's lead product candidate, SPX-1009, which is an anti-metastatic treatment and to measure levels of Quiescin Sulfhydryl Oxidase 1 (QSOX1) related to cancer. The Company is also engaged in point-of-care (POC) lab testing systems designed to assist eye-care physicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.

Contact Information

Headquarters
6191 Cornerstone Court, E, Suite 114SAN DIEGO, CA, United States 92121
Phone
212-751-0001
Fax
775-786-6755

Executives

President, Chief Executive Officer, Director
John Huemoeller
Chief Financial Officer, Company Secretary
Robert Malasek
Chief Executive Officer, Co-Founder of Sapphire Biotech, Inc.; Director
Catalina Valencia
Chief Medical Officer
Joseph Tauber
Director
Peter O'Rourke

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$8.6M
Revenue (TTM)
$6.1K
Shares Outstanding
186.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.33
EPS
$-0.10
Book Value
$-0.02
P/E Ratio
-0.4x
Price/Sales (TTM)
1,398.3
Price/Cash Flow (TTM)
---
Operating Margin
-191,002.80%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.